Share
2,040 Posts.
lightbulb Created with Sketch. 307
clock Created with Sketch. 04/10/24
14:47
Share
Here are some numbers played around with to start the discussion again on the upcoming quarterly. Assuming my estimated $1Million in product sales: Product Revenue US$1 million
Services Revenue (estimated)US$2.5 million (based on prior trends)
Total Revenue US$3.5 million
Operating Costs US$2.15 million (based on previous quarter estimates)
Net Cash Flow US$1.35 million (revenue minus costs)
Cash Position (Starting) US$6.5 million (as of Q4 FY2024)
Cash Position (End of Quarter) US$7.85 million (assuming steady cash burn)
Assuming a repeated $700,000 in product sales: Product Revenue US$700,000
Services Revenue (estimated)US$2.5 million (based on prior trends)
Total Revenue US$3.2 million
Operating Costs US$2.15 million (based on previous quarter estimates)
Net Cash Flow US$1.05 million (revenue minus costs)
Cash Position (Starting) US$6.5 million (as of Q4 FY2024)
Cash Position (End of Quarter) US$7.55 million (assuming steady cash burn)
Snapshot of the company's current position (Australian Dollars) : Total Revenue (FY2024) A$17.21 million
Product Revenue A$1.86 million
Commercial Services Revenue A$15.35 million
Operating Costs (FY2024) A$13.31 million
Key Funding A$4.62 million from BARDA for FebriDx® study
Cash Flow (Q4 FY2024) A$4.81 million positive
Cash Balance (End of FY2024) A$10.08 million
Hologic Agreements A$22.79 million (transformative agreements)
Hologic Payments Yet to be Received A$6.20 million yet to be received from Hologic agreements
Hologic Funding breakdown: January 2024 5,000,000 Non-refundable IP Agreement payment
June 2024 400,000 Milestone payment for fFN Development Agreement
June 2024 5,000,000 Second non-refundable payment under Hologic Agreement
September 2024 300,000 Milestone payment for further progress on development agreement
Yet to be received 4,000,000 Remaining payments under the Hologic Agreements
